Tomsk Cancer Research Institute of RAMS Tomsk Cancer Research Institute of RAMS

Russian || English

Last update
Thursday, 18-Jun-2015
17:20 NOVST



Evgeny L. Choynzonov MD, Academician of RAN, Professor, Director
Nadezhda V. Cherdyntseva Professor, Deputy Director for Basic Science
Victor E. Goldberg, MD, Professor, Deputy Director for Clinical Science
Vladimir I. Chernov, MD, Professor, Deputy Director for Science and Innovation

The history of Tomsk Cancer Research Institute dates back to June 29, 1979 when Siberian branch of the All-Union Cancer Research Center of the Russian Academy of Sciences was set up. Tomsk Scientific Center was founded in 1986 and Siberian branch of the All-Union Cancer Research Institute was reorganized into an independent institute. Since April, 2002 Professor Evgeny L. Choynzonov, MD, Academician of RAN has been Director of the Cancer Research Institute, Siberian Branch of Russian Academy of Sciences.

Today, we are ranked as the leading academic research Institute and the only Cancer Research Institute of in Siberia and the Russian Far East.

Our mission:

  • Eradication of cancer and the enhancement of the life quality of cancer patients.
  • Reducing the cancer incidence, cancer-related morbidity and mortality.
  • Advanced professional training
  • Use of leading-edge cancer research and biotechnologies to personalize treatment for each patient

The institute's staff contains approximately 500 employees including over 100 scientists and 50 clinicians.

Research and clinical scientists at the Institute are making a significant contribution to the prevention, early detection, diagnosis and treatment of cancer. In recent years, they have achieved major advances both in basic research and in the development of novel methods for clinical application.

Scientists are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. They are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer.

Basic Sciences Laboratories:

  • Epidemiology
  • Molecular Oncology and Immunology
  • Oncovirology
  • Tumor Biochemistry

The clinic of our Institute provides multidisciplinary care and high-tech cancer treatment for patients living in Siberia and Russian Far East. It is a 220 bedded hospital with state of the art facilities for the diagnosis and treatment of cancer. Annually, 3.5 thousand patients receive cutting-edge therapies and image-guided interventions.

Clinical Departments:

  • Anesthesiology and Intensive Care
  • Chemotherapy
  • Diagnostic Imaging
  • Radiation oncology
  • Nuclear Medicine
  • Endoscopy
  • Outpatient Diagnostic Center
  • Hospital-Based Cancer Registry
  • Pharmacy
Surgical oncology:
  • Head & Neck Cancer Unit
  • Breast Cancer Unit
  • Bone and Soft Tissue Cancer Unit
  • Urologic Cancer Unit
  • Gastrointestinal Cancer Unit
  • Thoracic Cancer Unit
  • Gynecological Cancer Unit
Major fundamental research interests are:
  • To study cancer incidence, cancer-based morbidity and mortality in different ethnic populations on the territory of Siberia and the Russian Far East
  • To reveal endogenous and exogenous etiological factors and their complexes to improve organization of cancer care for the population of the region
  • To discover genetic and other molecular changes in tumor and tumor microenvironment to determine their role in clinical behavior and establish new molecular diagnostics and novel molecular therapeutic targets in cancer.
  • To study molecular mechanisms of breast cancer metastasis based on Lyden's metaststic niche concept and Paget "seed and soil" hypothesis as a platform for metastatic disease prediction and prevention.
  • To develop molecular diagnostic assays for routine clinical use in oncology practice.
  • To characterize mechanisms of resistance to therapies by integrating molecular profiling and functional genomics.
  • To promote rapid translation of basic discoveries of cancer mechanisms into the development of potential prognostic markers and therapeutic strategies.
  • To develop the most effective, safe, and cost-effective approaches for predictive, preventive and personalized oncology.

Results obtained from fundamental researches are translated into clinical applications.


  • Intraoperative radiation therapy (IORT), a new treatment modality, has been developed in our Institute. IORT is performed immediately in the operating room using a compact 6.3 MeV betatron. A large single radiation dose is delivered to the bed of the removed tumor enhancing the anti-tumor effects while sparing surrounding normal tissues from radiation-induced damage. Advances: no patient transportation to the radiological department is required, minimization of radiation load to the patient, decrease in the treatment costs and increase in the 5-year survival rate.
  • Extensive clinical experience of the use of neutron therapy for treatment of patients with malignant tumors resistant to photon therapy has been accumulated. The appropriate selection of the fractionation regimen for preoperative neutron therapy in the treatment of cancer patients permits radical surgery to be performed and long-term damage to normal tissues to be avoided, thus reducing the incidence of local recurrences and increasing relapse-free survival time.
  • Novel approaches to organ-preserving and plastic reconstructive surgeries with the use of cutting-edge medical equipment, endoprostheses from the porous titanium nickelid and microsurgical autografting have been worked out. It allows to increase the treatment efficacy, to reduce rehabilitation period and to improve life quality of patients.
  • The unique technique of vocal function recovery using mathematical model-based biological feedback for rehabilitation of laryngectomized cancer patients has been developed.
  • Molecular genetic testing for: 1) detection of somatic mutations to indentify an appropriate targeted therapy, 2) detection of hereditary mutations associated with family cancer to provide the early diagnostics and adequate therapy. 3) detection of chromosomal aberration in tumor DNA to predict the tumor response to neoadjuvant chemotherapy in breast cancer patients and choose the relevant treatment.

About personalized therapy

No two cancers are alike, just as no two people are alike. Our goal is to transform cancer therapy by using advanced technological tools to predict who will respond to a specific treatment, and to match each patient with the best drug for a particular tumor.

Recent technological advances have made it possible to generate a profile of the abnormalities in the genetic code of a tumor. By gathering enough data, we can identify profiles that will allow us to begin to tailor cancer treatments to individual patients.

Family Cancer Genetics Program

We provide patients with the latest information about inherited cancer risks, available genetic testing, and options for individuals known to be at a high risk of developing cancer due to genetic predisposition.

Siberian Journal of Oncology

The Journal was founded in 2002. The Cancer Research Institute is a founder of Siberian journal of oncology. Published twice monthly, it has an impact factor of 0.4 in Russian Science Citation Index. All articles are freely available online. The Siberian Journal of Oncology is a peer-reviewed and multidisciplinary journal that publishes original articles in the field of clinical and experimental oncology. The journal covers the following areas of interest: carcinogenesis, molecular biology, pathology, epidemiology, prevention, diagnostic techniques, surgery, chemotherapy, radiotherapy, anesthesiology, rehabilitation and experimental studies.


The Institute provides high quality educational activity and training in oncology for:

  • students of Siberian State Medical University (Department of Oncology)
  • students of National Research Tomsk State University
  • postgraduate students in specialty of oncology, diagnostic imaging and radiation therapy
  • resident physicians in specialty of oncology and radiology
  • medical interns

There is a Coordinating Council of Young Scientists in the Institute, which represents a community of postdoctoral research fellows, who carry out high quality research and are usually involved in research projects. They arrange various scientific activities and participate in regional, national and international scientific conferences and workshops.

The Institute has a Dissertation Board for obtaining Doctor of Science (DSc) degree and PhD degree in oncology and radio diagnostics and radiotherapy.

The Institute provides the perfect environment for developing and nurturing a scientific career.


Aim: to promote collaboration between scientists, healthcare professionals, business, industry and governmental bodies.

The Institute cooperates with various medical and technical organizations and actively participates in cooperated Russian and International researches on the efficacy of anti-tumor drugs and in programs of joined researches. The Institute continuously organizes various scientific conferences, seminars, meetings and workshops.

Our partners:

  • Tomsk State University (Tomsk, Russia)
  • National Research Tomsk Polytechnic University (Tomsk, Russia)
  • Research Institute of High Tensions, Tomsk Polytechnic University (Tomsk, Russia)
  • The Siberian State Medical University (Tomsk, Russia)
  • Institute of High-Current Electronics, Siberian Branch of the Russian Academy of Sciences (Tomsk, Russia)
  • Tomsk State University of Control Systems and Radio Electronics (Tomsk, Russia)
  • Research Institute of Medical Genetics, Siberian Branch of the Russian Academy of Medical Sciences (Tomsk, Russia)
  • Research Institute for Cardiology (Tomsk, Russia)
  • Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences (Novosibirsk, Russia)
  • Therapy Research Institute, Siberian Branch of the Russian Academy of Sciences (Novosibirsk, Russia)
  • M.M.Shemyakin and Yu.A.Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (Moscow, Russia)
  • N.N. Blokhin Russian Cancer Research Center of Russian Academy of Sciences, (Moscow, Russia)
  • P.A. Gertsen Moscow Research Institute of Oncology (Moscow, Russia)
  • Koltzov Institute of Developmental Biology(Moscow, Russia)
  • V.A. Engelhardt Institute of Molecular Biology of the RAS, Moscow
  • N.N. Petrov Research Institute of Oncology (St-Petersburg, Russia)
  • North Kazakhstan State University named after M. Kozybaev (Kazakhstan)
  • European Society of Gynecological Oncology (ESGO)
  • European Organization for Research and Treatment of Cancer (EORTC) (Brussels, Netherlands)
  • Cureline East Research LLC (San Francisco CA, USA)
  • Toyama Medical and Pharmaceutical University (Japan)
  • Sun Yat-sen University Cancer Center (Guanchzhou, China)
  • Memorial Hospital Chung-Kan Tsao (Taiwan)
  • Amrita Institute of Medical Sciences (Cotchi, India)
  • Heidelberg University (Germany)
  • University of Zurich (Switzerland)


There have been published 118 monographs, 57 collected articles and 52 guidelines.

Our researches are funded by the Russian Fund of Basic Research, the Russian Federation President Grant, Federal Target program "Development of The Pharmaceutical and Medical Technology Industry of The Russian Federation for the period till 2020 and beyond" of the Ministry of Economic Development of the Russian Federation, the Ministry of Industry and Trade of the Russian Federation, Federal Target Program " Research and development in priority directions of scientific -technological complex of Russia", Federal Target Program "Research and scientific-educational personnel of innovative Russia", Russian Science Foundation.

Up   |   Back

5 Kooperativny Street
634050 Tomsk
+7 3822 511039
+7 3822 514097